- Home
- TUYA vs CGON Comparison
TUYA vs CGON Comparison
Compare TUYA & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TUYA
- CGON
- Stock Information
- Founded
- TUYA 2014
- CGON 2010
- Country
- TUYA China
- CGON United States
- Employees
- TUYA N/A
- CGON N/A
- Industry
- TUYA Computer Software: Prepackaged Software
- CGON
- Sector
- TUYA Technology
- CGON
- Exchange
- TUYA Nasdaq
- CGON NYSE
- Market Cap
- TUYA 1.6B
- CGON 1.3B
- IPO Year
- TUYA 2021
- CGON 2024
- Fundamental
- Price
- TUYA $2.42
- CGON $25.62
- Analyst Decision
- TUYA
- CGON Strong Buy
- Analyst Count
- TUYA 0
- CGON 10
- Target Price
- TUYA N/A
- CGON $64.00
- AVG Volume (30 Days)
- TUYA 2.5M
- CGON 1.4M
- Earning Date
- TUYA 05-20-2025
- CGON 05-13-2025
- Dividend Yield
- TUYA 4.50%
- CGON N/A
- EPS Growth
- TUYA N/A
- CGON N/A
- EPS
- TUYA 0.03
- CGON N/A
- Revenue
- TUYA $311,642,000.00
- CGON $662,000.00
- Revenue This Year
- TUYA $20.05
- CGON N/A
- Revenue Next Year
- TUYA $17.58
- CGON $12,387.03
- P/E Ratio
- TUYA $72.46
- CGON N/A
- Revenue Growth
- TUYA 27.64
- CGON 224.51
- 52 Week Low
- TUYA $1.28
- CGON $14.80
- 52 Week High
- TUYA $4.63
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- TUYA 46.28
- CGON 53.27
- Support Level
- TUYA $2.35
- CGON $24.79
- Resistance Level
- TUYA $2.66
- CGON $26.60
- Average True Range (ATR)
- TUYA 0.15
- CGON 1.39
- MACD
- TUYA 0.00
- CGON -0.01
- Stochastic Oscillator
- TUYA 12.50
- CGON 48.52
About TUYA Tuya Inc. each representing one
Tuya Inc is an IoT cloud development platform with a mission to build an IoT developer ecosystem and enable everything to be smart. The Company has pioneered a purpose-built IoT cloud development platform that delivers a full suite of offerings, including platform-as-a-service (PaaS) and Software-as-a-service (SaaS), to businesses and developers. Through its IoT cloud development platform, it has enabled developers to activate a vibrant IoT ecosystem of brands, OEMs, partners, and end users to engage and communicate through a broad range of smart devices. The company's revenue is derived from the PRC.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.